EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies

Raffaella Cassano Cassano, Angelo Giovanni Bonadio, Maria Livia Del Giudice, Domenico Giannese, Sara Galimberti, Gabriele Buda

Annals of Hematology · 2025-04 · 104 (4) · 2083-2093

DOI: 10.1007/s00277-024-05911-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 28.08.2024. Verfasst von Raffaella Cassano Cassano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126, Pisa, Italy. cassano462@gmail.com. Hauptthemen laut MEDLINE: Immunoglobulin Light Chains, Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light chain deposition disease (LCDD) is a rare hematologic disorder characterized by the deposition of non-amyloid monoclonal light chains in several organs. Together with renal impairment is being the primary morbidity associated with this disease. Due to its rarity, randomized clinical trials lack to explore treatment strategies and there are no approved or universally accepted standard of care treatment options. We aimed to provide a systematic summary of histological and clinical aspects of LCDD and treatment options of available literature therapies strategies. Currently, drugs used to treat multiple myeloma are recommended when LCDD patients also presented multiple myeloma. Anyway, in patients with LCDD that is not associated to multiple myeloma, haematopoietic stem cell transplantation (ASCT) and chemotherapy with thalidomide, dexamethasone, bortezomib are also recommended. In eligible patients, bortezomib-based chemotherapy followed by ASCT appears to be an effective treatment option with durable hematologic remission and organ responses. Although it appears that the patients undergoing ASCT seem to achieve deeper and durable hematologic remissions and organ responses, no statistically significant superiority can be demonstrated over non-transplant or standard chemotherapy-based approaches. As retrieved by our review, bortezomib-based therapy appears to be favorable strategy as long as no dose modification is required for renal impairment, and early hematologic responses as a recovery of renal function. Encouraging data were also demonstrated by treatment lenalidomide or melpalan based. Moreover, new myeloma treatment strategies, as monoclonal antibody Daratumumab, seem to be effective in LCDD. Instead, renal allograft is not recommended, due to high incidence of relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light ChainsImmunoglobulin Light-chain AmyloidosisHumansHematopoietic Stem Cell TransplantationBortezomibMultiple MyelomaAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Autologus stem cells transplantLCDDLight chain deposition diseaseMGRSMonoclonal gammopathyPlasma cells

Substanzen

BortezomibImmunoglobulin Light Chains

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126, Pisa, Italy. cassano462@gmail.com.
  • Department of Surgical, Medical, Molecular Pathology and Critical Area, Division of Surgical Pathology II, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, Nephrology Unit, University of Pisa, 56126, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126, Pisa, Italy. gabriele.buda@unipi.it.

Förderung

  • Università di Pisa

Zitieren

APA

Cassano Cassano, R., Bonadio, A. G., Del Giudice, M. L., Giannese, D., Galimberti, S., & Buda, G. (2025). Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies. Annals of Hematology, 104(4), 2083-2093. https://doi.org/10.1007/s00277-024-05911-9

Vancouver

Cassano Cassano R, Bonadio AG, Del Giudice ML, Giannese D, Galimberti S, Buda G. Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies. Annals of Hematology. 2025;104(4):2083-2093. doi:10.1007/s00277-024-05911-9

BibTeX
@article{CassanoCassano2025,
  author = {Cassano Cassano, Raffaella and Bonadio, Angelo Giovanni and Del Giudice, Maria Livia and Giannese, Domenico and Galimberti, Sara and Buda, Gabriele},
  title = {Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {4},
  pages = {2083--2093},
  doi = {10.1007/s00277-024-05911-9}
}
Kostenlos starten →